OmniAb (NASDAQ:OABI) Releases Earnings Results, Beats Expectations By $0.01 EPS

Key Points

• OmniAb beat quarterly expectations: The company reported a loss of $0.12 per share versus the expected $0.13 loss, while revenue reached $3.99 million compared with the $3.49 million consensus estimate.
• 2026 guidance was raised: OmniAb now expects revenue of $35 million–$39 million, operating expenses of $83 million–$87 million, and year-end cash of $53 million–$57 million, implying roughly break-even net cash flow.
• Partnership momentum strengthened: A new Eli Lilly license includes an upfront payment, up to $370 million in potential milestones and tiered royalties; the company also reported 111 partners, 433 active programs and growing commercial traction for its xPloration platform.

OmniAb (NASDAQ:OABI - Get Free Report) issued its earnings results on Friday. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.01, FiscalAI reports. The firm had revenue of $3.99 million for the quarter, compared to the consensus estimate of $3.49 million. OmniAb had a negative return on equity of 16.59% and a negative net margin of 115.12%.

Here are the key takeaways from OmniAb's conference call:

• 2026 guidance was raised: OmniAb increased revenue guidance to $35 million–$39 million, reduced operating-expense guidance to $83 million–$87 million, and expects year-end cash of $53 million–$57 million, implying roughly break-even net cash flow for the year.
• The company signed a new Eli Lilly ion-channel license that includes an upfront payment, up to $370 million in potential milestones, and tiered royalties; related service revenue is expected to begin in the fourth quarter.
• Partner momentum continued, with 111 active partners and 433 active programs at quarter-end. OmniAb also reported 34 active clinical programs or approved products, more than $3 billion in contracted potential milestones, and the recent Chinese approval of batoclimab.
• xPloration gained commercial traction with another instrument placement at a major pharmaceutical company. Management expects xPloration revenue of $2 million–$3 million in 2026, followed by a doubling in 2027 and again in 2028 as consumables, software, and service revenue build.
• Third-quarter revenue rose to $4.0 million from $2.2 million, while net loss narrowed modestly to $15.7 million, or $0.12 per share. Management expects milestones to remain the largest revenue contributor over the next several years, with royalties potentially becoming a larger growth driver as assets such as IMVT-1402 advance.

OmniAb Stock Down 3.0%

Shares of OmniAb stock traded down $0.16 on Friday, reaching $5.07. The company's stock had a trading volume of 1,752,475 shares, compared to its average volume of 884,322. The firm's fifty day simple moving average is $4.64 and its two-hundred day simple moving average is $2.69. OmniAb has a 52 week low of $1.30 and a 52 week high of $5.43. The company has a market capitalization of $734.47 million, a price-to-earnings ratio of -14.09 and a beta of 0.60.

Analysts Set New Price Targets

OABI has been the topic of a number of research reports. HC Wainwright reiterated a "buy" rating and set a $11.00 target price on shares of OmniAb in a research report on Monday, August 17th. Leerink Partners upped their target price on OmniAb from $10.00 to $12.00 and gave the company an "outperform" rating in a report on Wednesday, October 7th. Finally, Weiss Ratings raised shares of OmniAb from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, August 20th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, OmniAb currently has an average rating of "Moderate Buy" and a consensus target price of $11.50.

About OmniAb

OmniAb, Inc is a biotechnology company that develops and licenses antibody discovery technologies for use in drug research and development. Its platform is designed to help biopharmaceutical companies generate fully human and species-diverse antibodies that can be evaluated as potential treatments for a range of diseases.

The company's technology portfolio includes genetically engineered animal platforms, such as OmniRat, OmniMouse and OmniChicken, which are used to produce antibody candidates against challenging biological targets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.